Discovery - University of Dundee - Online Publications

Library & Learning Centre

Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase

Standard

Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase : implications for increasing the activity against sensitive and multidrug-resistant leukaemia HL60 cells. / Kostrzewa-Nowak, Dorota; Bieg, Bohdan; Paine, Mark J. I.; Wolf, C. Roland; Tarasiuk, Jolanta.

In: Anti-Cancer Drugs, Vol. 23, No. 4, 01.04.2012, p. 393-405.

Research output: Contribution to journalArticle

Harvard

Kostrzewa-Nowak, D, Bieg, B, Paine, MJI, Wolf, CR & Tarasiuk, J 2012, 'Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase: implications for increasing the activity against sensitive and multidrug-resistant leukaemia HL60 cells' Anti-Cancer Drugs, vol 23, no. 4, pp. 393-405., 10.1097/CAD.0b013e32834fcf4f

APA

Kostrzewa-Nowak, D., Bieg, B., Paine, M. J. I., Wolf, C. R., & Tarasiuk, J. (2012). Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase: implications for increasing the activity against sensitive and multidrug-resistant leukaemia HL60 cells. Anti-Cancer Drugs, 23(4), 393-405. 10.1097/CAD.0b013e32834fcf4f

Vancouver

Kostrzewa-Nowak D, Bieg B, Paine MJI, Wolf CR, Tarasiuk J. Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase: implications for increasing the activity against sensitive and multidrug-resistant leukaemia HL60 cells. Anti-Cancer Drugs. 2012 Apr 1;23(4):393-405. Available from: 10.1097/CAD.0b013e32834fcf4f

Author

Kostrzewa-Nowak, Dorota; Bieg, Bohdan; Paine, Mark J. I.; Wolf, C. Roland; Tarasiuk, Jolanta / Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase : implications for increasing the activity against sensitive and multidrug-resistant leukaemia HL60 cells.

In: Anti-Cancer Drugs, Vol. 23, No. 4, 01.04.2012, p. 393-405.

Research output: Contribution to journalArticle

Bibtex - Download

@article{7ac72383f8d04d44bb8d18a2ae6dee32,
title = "Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase: implications for increasing the activity against sensitive and multidrug-resistant leukaemia HL60 cells",
author = "Dorota Kostrzewa-Nowak and Bohdan Bieg and Paine, {Mark J. I.} and Wolf, {C. Roland} and Jolanta Tarasiuk",
year = "2012",
doi = "10.1097/CAD.0b013e32834fcf4f",
volume = "23",
number = "4",
pages = "393--405",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase

T2 - implications for increasing the activity against sensitive and multidrug-resistant leukaemia HL60 cells

A1 - Kostrzewa-Nowak,Dorota

A1 - Bieg,Bohdan

A1 - Paine,Mark J. I.

A1 - Wolf,C. Roland

A1 - Tarasiuk,Jolanta

AU - Kostrzewa-Nowak,Dorota

AU - Bieg,Bohdan

AU - Paine,Mark J. I.

AU - Wolf,C. Roland

AU - Tarasiuk,Jolanta

PY - 2012/4/1

Y1 - 2012/4/1

N2 - The aim of this study was to examine the role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase (CPR) and determine the impact of this activation on increasing the activity especially with regard to multidrug resistant (MDR) tumour cells. It was found that at a high NADPH concentration (500 µmol/l), the anthracenedione agent ametantrone, with an unmodified quinone structure, was susceptible to CPR-dependent reductive activation. In contrast, it was shown that compounds with modified quinone grouping (benzoperimidine BP1, anthrapyridone CO1 and pyrazolopyrimidoacridine PPAC2) did not undergo reductive activation by CPR. This suggests that the presence of a modified quinone function is the structural factor excluding reductive activation of antitumour anthraquinone derivatives and analogues by CPR. In the second part of the work, the ability of antitumour anthraquinone derivatives and analogues to inhibit the growth of the human promyelocytic, sensitive leukaemia HL60 cell line as well as its MDR sublines exhibiting two different phenotypes of MDR related to the overexpression of P-glycoprotein (HL60/VINC) or MRP1 (HL60/DOX) was studied in the presence of exogenously added CPR. A significant increase in the activity of ametantrone with an unmodified quinone structure after its reductive conversion by CPR was observed against HL60 as well as HL60/VINC and HL60/DOX cells, whereas in the case of quinone-modified compounds (BP1, CO1 and PPAC2), the presence of the activation system had no effect on their activity against the sensitive and MDR tumour cells examined. © 2012 Lippincott Williams & Wilkins, Inc.

AB - The aim of this study was to examine the role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase (CPR) and determine the impact of this activation on increasing the activity especially with regard to multidrug resistant (MDR) tumour cells. It was found that at a high NADPH concentration (500 µmol/l), the anthracenedione agent ametantrone, with an unmodified quinone structure, was susceptible to CPR-dependent reductive activation. In contrast, it was shown that compounds with modified quinone grouping (benzoperimidine BP1, anthrapyridone CO1 and pyrazolopyrimidoacridine PPAC2) did not undergo reductive activation by CPR. This suggests that the presence of a modified quinone function is the structural factor excluding reductive activation of antitumour anthraquinone derivatives and analogues by CPR. In the second part of the work, the ability of antitumour anthraquinone derivatives and analogues to inhibit the growth of the human promyelocytic, sensitive leukaemia HL60 cell line as well as its MDR sublines exhibiting two different phenotypes of MDR related to the overexpression of P-glycoprotein (HL60/VINC) or MRP1 (HL60/DOX) was studied in the presence of exogenously added CPR. A significant increase in the activity of ametantrone with an unmodified quinone structure after its reductive conversion by CPR was observed against HL60 as well as HL60/VINC and HL60/DOX cells, whereas in the case of quinone-modified compounds (BP1, CO1 and PPAC2), the presence of the activation system had no effect on their activity against the sensitive and MDR tumour cells examined. © 2012 Lippincott Williams & Wilkins, Inc.

UR - http://www.scopus.com/inward/record.url?scp=84858279447&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e32834fcf4f

DO - 10.1097/CAD.0b013e32834fcf4f

M1 - Article

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 4

VL - 23

SP - 393

EP - 405

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy